D
enVVeno Medical Corporation
NVNO
$2.48
-$0.11-4.25%
D
Sell
3/27/2025Upgraded
enVVeno Medical Corporation (NVNO) was upgraded to D- from E+ on 3/27/2025 due to an increase in the growth index, volatility index and total return index.
enVVeno Medical Corporation (NVNO) was upgraded to D- from E+ on 3/27/2025 due to an increase in the growth index, volatility index and total return index.
E
Sell
3/11/2025Downgrade
enVVeno Medical Corporation (NVNO) was downgraded to E+ from D- on 3/11/2025 due to a decline in the volatility index and valuation index.
enVVeno Medical Corporation (NVNO) was downgraded to E+ from D- on 3/11/2025 due to a decline in the volatility index and valuation index.
D
Sell
8/17/2023Upgraded
enVVeno Medical Corporation (NVNO) was upgraded to D- from E+ on 8/17/2023 due to an increase in the volatility index and total return index.
enVVeno Medical Corporation (NVNO) was upgraded to D- from E+ on 8/17/2023 due to an increase in the volatility index and total return index.
E
Sell
8/2/2023Downgrade
enVVeno Medical Corporation (NVNO) was downgraded to E+ from D- on 8/2/2023 due to a decline in the solvency index, volatility index and valuation index. The quick ratio declined from 29.31 to 14.4.
enVVeno Medical Corporation (NVNO) was downgraded to E+ from D- on 8/2/2023 due to a decline in the solvency index, volatility index and valuation index. The quick ratio declined from 29.31 to 14.4.
D
Sell
7/13/2023Upgraded
enVVeno Medical Corporation (NVNO) was upgraded to D- from E+ on 7/13/2023 due to an increase in the volatility index.
enVVeno Medical Corporation (NVNO) was upgraded to D- from E+ on 7/13/2023 due to an increase in the volatility index.
E
Sell
6/27/2023Downgrade
enVVeno Medical Corporation (NVNO) was downgraded to E+ from D- on 6/27/2023 due to a decline in the total return index, volatility index and growth index. Operating cash flow declined 32.49% from -$3.86M to -$5.11M, EBIT declined 5.22% from -$6.46M to -$6.8M, and earnings per share declined from -$0.6524 to -$0.6748.
enVVeno Medical Corporation (NVNO) was downgraded to E+ from D- on 6/27/2023 due to a decline in the total return index, volatility index and growth index. Operating cash flow declined 32.49% from -$3.86M to -$5.11M, EBIT declined 5.22% from -$6.46M to -$6.8M, and earnings per share declined from -$0.6524 to -$0.6748.
D
Sell
3/8/2023Downgrade
enVVeno Medical Corporation (NVNO) was downgraded to D- from D on 3/8/2023 due to a large decline in the growth index, solvency index and total return index. The quick ratio declined from 30.93 to 25.52, EBIT declined 5.02% from -$6.15M to -$6.46M, and earnings per share declined from -$0.6437 to -$0.6524.
enVVeno Medical Corporation (NVNO) was downgraded to D- from D on 3/8/2023 due to a large decline in the growth index, solvency index and total return index. The quick ratio declined from 30.93 to 25.52, EBIT declined 5.02% from -$6.15M to -$6.46M, and earnings per share declined from -$0.6437 to -$0.6524.
D
Sell
2/23/2023Upgraded
enVVeno Medical Corporation (NVNO) was upgraded to D from D- on 02/23/2023.
enVVeno Medical Corporation (NVNO) was upgraded to D from D- on 02/23/2023.
D
Sell
2/8/2023Downgrade
enVVeno Medical Corporation (NVNO) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index.
enVVeno Medical Corporation (NVNO) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index.
D
Sell
9/9/2022Upgraded
enVVeno Medical Corporation (NVNO) was upgraded to D from D- on 9/9/2022 due to an increase in the total return index and volatility index.
enVVeno Medical Corporation (NVNO) was upgraded to D from D- on 9/9/2022 due to an increase in the total return index and volatility index.
D
Sell
8/9/2022Downgrade
enVVeno Medical Corporation (NVNO) was downgraded to D- from D on 8/9/2022 due to a noticeable decline in the growth index, volatility index and solvency index. The quick ratio declined from 40.42 to 20.66, earnings per share declined from -$0.5628 to -$0.7457, and EBIT declined 30.95% from -$5.34M to -$6.99M.
enVVeno Medical Corporation (NVNO) was downgraded to D- from D on 8/9/2022 due to a noticeable decline in the growth index, volatility index and solvency index. The quick ratio declined from 40.42 to 20.66, earnings per share declined from -$0.5628 to -$0.7457, and EBIT declined 30.95% from -$5.34M to -$6.99M.
D
Sell
5/16/2022Upgraded
enVVeno Medical Corporation (NVNO) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
enVVeno Medical Corporation (NVNO) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
enVVeno Medical Corporation (NVNO) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
enVVeno Medical Corporation (NVNO) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/4/2022Upgraded
enVVeno Medical Corporation (NVNO) was upgraded to D from E+ on 05/04/2022.
enVVeno Medical Corporation (NVNO) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
enVVeno Medical Corporation (NVNO) was downgraded to E+ from D on 05/01/2022.
enVVeno Medical Corporation (NVNO) was downgraded to E+ from D on 05/01/2022.
D
Sell
4/29/2022Upgraded
enVVeno Medical Corporation (NVNO) was upgraded to D from D- on 4/29/2022 due to a substantial increase in the growth index and valuation index. Earnings per share increased from -$0.8026 to -$0.4747, and EBIT increased 40.67% from -$8.99M to -$5.34M.
enVVeno Medical Corporation (NVNO) was upgraded to D from D- on 4/29/2022 due to a substantial increase in the growth index and valuation index. Earnings per share increased from -$0.8026 to -$0.4747, and EBIT increased 40.67% from -$8.99M to -$5.34M.
D
Sell
4/18/2022Upgraded
enVVeno Medical Corporation (NVNO) was upgraded to D- from E+ on 4/18/2022 due to an increase in the volatility index.
enVVeno Medical Corporation (NVNO) was upgraded to D- from E+ on 4/18/2022 due to an increase in the volatility index.
E
Sell
3/30/2022Downgrade
enVVeno Medical Corporation (NVNO) was downgraded to E+ from D- on 3/30/2022 due to a decline in the volatility index.
enVVeno Medical Corporation (NVNO) was downgraded to E+ from D- on 3/30/2022 due to a decline in the volatility index.
D
Sell
3/29/2022Downgrade
enVVeno Medical Corporation (NVNO) was downgraded to D- from D on 3/29/2022 due to a major decline in the growth index, total return index and volatility index. EBIT declined 232.25% from -$2.71M to -$8.99M, earnings per share declined from -$0.2603 to -$0.8026, and operating cash flow declined 38.75% from -$2.23M to -$3.1M.
enVVeno Medical Corporation (NVNO) was downgraded to D- from D on 3/29/2022 due to a major decline in the growth index, total return index and volatility index. EBIT declined 232.25% from -$2.71M to -$8.99M, earnings per share declined from -$0.2603 to -$0.8026, and operating cash flow declined 38.75% from -$2.23M to -$3.1M.
D
Sell
11/15/2021Upgraded
enVVeno Medical Corporation (NVNO) was upgraded to D from D- on 11/15/2021 due to an increase in the solvency index and volatility index. The quick ratio increased from 29.45 to 51.78, and debt to equity declined from 0.02 to 0.01.
enVVeno Medical Corporation (NVNO) was upgraded to D from D- on 11/15/2021 due to an increase in the solvency index and volatility index. The quick ratio increased from 29.45 to 51.78, and debt to equity declined from 0.02 to 0.01.
D
Sell
11/8/2021Downgrade
enVVeno Medical Corporation (NVNO) was downgraded to D- from D on 11/08/2021.
enVVeno Medical Corporation (NVNO) was downgraded to D- from D on 11/08/2021.
D
Sell
9/1/2021Upgraded
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to D from D- on 9/1/2021 due to an increase in the total return index and volatility index.
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to D from D- on 9/1/2021 due to an increase in the total return index and volatility index.
D
Sell
8/17/2021Downgrade
Hancock Jaffe Laboratories, Inc. (HJLI) was downgraded to D- from D on 8/17/2021 due to a decline in the volatility index, growth index and solvency index. Debt to equity increased from 0.01 to 0.02.
Hancock Jaffe Laboratories, Inc. (HJLI) was downgraded to D- from D on 8/17/2021 due to a decline in the volatility index, growth index and solvency index. Debt to equity increased from 0.01 to 0.02.
D
Sell
7/29/2021Upgraded
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to D from D- on 7/29/2021 due to an increase in the volatility index.
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to D from D- on 7/29/2021 due to an increase in the volatility index.
D
Sell
7/13/2021Downgrade
Hancock Jaffe Laboratories, Inc. (HJLI) was downgraded to D- from D on 7/13/2021 due to a decline in the volatility index and total return index.
Hancock Jaffe Laboratories, Inc. (HJLI) was downgraded to D- from D on 7/13/2021 due to a decline in the volatility index and total return index.
D
Sell
6/22/2021Upgraded
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to D from D- on 6/22/2021 due to an increase in the volatility index and total return index.
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to D from D- on 6/22/2021 due to an increase in the volatility index and total return index.
D
Sell
6/7/2021Downgrade
Hancock Jaffe Laboratories, Inc. (HJLI) was downgraded to D- from D on 6/7/2021 due to a decline in the volatility index.
Hancock Jaffe Laboratories, Inc. (HJLI) was downgraded to D- from D on 6/7/2021 due to a decline in the volatility index.
D
Sell
5/18/2021Upgraded
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to D from D- on 5/18/2021 due to a major increase in the growth index, solvency index and volatility index. The quick ratio increased from 2.93 to 23.39, debt to equity declined from 0.09 to 0.01, and earnings per share increased from -$2.3488 to -$0.483.
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to D from D- on 5/18/2021 due to a major increase in the growth index, solvency index and volatility index. The quick ratio increased from 2.93 to 23.39, debt to equity declined from 0.09 to 0.01, and earnings per share increased from -$2.3488 to -$0.483.
D
Sell
5/3/2021Upgraded
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to D- from E+ on 5/3/2021 due to an increase in the volatility index.
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to D- from E+ on 5/3/2021 due to an increase in the volatility index.
E
Sell
4/16/2021Downgrade
Hancock Jaffe Laboratories, Inc. (HJLI) was downgraded to E+ from D- on 4/16/2021 due to a decline in the growth index and volatility index. EBIT declined 116.32% from -$1.92M to -$4.16M, earnings per share declined from -$1.3823 to -$2.3488, and operating cash flow declined 0.85% from -$2.59M to -$2.61M.
Hancock Jaffe Laboratories, Inc. (HJLI) was downgraded to E+ from D- on 4/16/2021 due to a decline in the growth index and volatility index. EBIT declined 116.32% from -$1.92M to -$4.16M, earnings per share declined from -$1.3823 to -$2.3488, and operating cash flow declined 0.85% from -$2.59M to -$2.61M.
D
Sell
8/14/2020Downgrade
Hancock Jaffe Laboratories, Inc. (HJLI) was downgraded to D- from D on 8/14/2020 due to a noticeable decline in the growth index and valuation index. Earnings per share declined from -$0.0629 to -$0.08, operating cash flow declined 14.55% from -$1.15M to -$1.32M, and EBIT declined 2.48% from -$1.51M to -$1.55M.
Hancock Jaffe Laboratories, Inc. (HJLI) was downgraded to D- from D on 8/14/2020 due to a noticeable decline in the growth index and valuation index. Earnings per share declined from -$0.0629 to -$0.08, operating cash flow declined 14.55% from -$1.15M to -$1.32M, and EBIT declined 2.48% from -$1.51M to -$1.55M.
D
Sell
6/9/2020Upgraded
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to D from D- on 6/9/2020 due to a noticeable increase in the growth index and valuation index. Earnings per share increased from -$0.1276 to -$0.0629, operating cash flow increased 29.02% from -$1.62M to -$1.15M, and EBIT increased 11.79% from -$1.71M to -$1.51M.
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to D from D- on 6/9/2020 due to a noticeable increase in the growth index and valuation index. Earnings per share increased from -$0.1276 to -$0.0629, operating cash flow increased 29.02% from -$1.62M to -$1.15M, and EBIT increased 11.79% from -$1.71M to -$1.51M.
D
Sell
5/20/2020Upgraded
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to D- from E+ on 5/20/2020 due to an increase in the growth index and valuation index.
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to D- from E+ on 5/20/2020 due to an increase in the growth index and valuation index.
E
Sell
5/1/2020Downgrade
Hancock Jaffe Laboratories, Inc. (HJLI) was downgraded to E+ from D- on 5/1/2020 due to a large decline in the growth index, efficiency index and total return index. Total capital declined 53.91% from $4.01M to $1.85M, net income declined 26.22% from -$1.81M to -$2.29M, and earnings per share declined from -$0.1013 to -$0.1276.
Hancock Jaffe Laboratories, Inc. (HJLI) was downgraded to E+ from D- on 5/1/2020 due to a large decline in the growth index, efficiency index and total return index. Total capital declined 53.91% from $4.01M to $1.85M, net income declined 26.22% from -$1.81M to -$2.29M, and earnings per share declined from -$0.1013 to -$0.1276.
D
Sell
5/15/2019Upgraded
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to D- from E+ on 5/15/2019 due to a major increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.1517 to -$0.13, and total revenue increased 2.3% from $30.5 to $31.2.
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to D- from E+ on 5/15/2019 due to a major increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.1517 to -$0.13, and total revenue increased 2.3% from $30.5 to $31.2.
E
Sell
2/1/2019Upgraded
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to E+ from E on 2/1/2019 due to an increase in the solvency index.
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to E+ from E on 2/1/2019 due to an increase in the solvency index.
E
Sell
11/1/2018Upgraded
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to E from E- on 11/1/2018 due to a noticeable increase in the efficiency index, growth index and total return index.
Hancock Jaffe Laboratories, Inc. (HJLI) was upgraded to E from E- on 11/1/2018 due to a noticeable increase in the efficiency index, growth index and total return index.
E
Sell
8/23/2018None
enVVeno Medical Corporation (NVNO) was downgraded to E- from U on 08/23/2018.
enVVeno Medical Corporation (NVNO) was downgraded to E- from U on 08/23/2018.
NASDAQ
04/03/2025 4:00PM Eastern
Quotes delayed
